Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNMT | P11086 | 7/20 | 0.50 |
| ▸ | ADRA2A | P08913 | 3/20 | 0.50 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.50 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.50 |
| ▸ | DRD2 | P14416 | 1/20 | 0.46 |
| ▸ | DRD3 | P35462 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL330080 | 0.88 | PNMT (0.60) | PNMTADRA2AADRA2BADRA2CDRD2 | |
| SCHEMBL29521679 | 0.88 | PNMT (0.60) | PNMTADRA2AADRA2BADRA2CDRD2 | |
| Hydrochloric Acid SCHEMBL4517857 | 0.86 | PNMT (0.58) | PNMTADRA2AADRA2BADRA2CDRD2 | |
| Hydrochloric Acid SCHEMBL3285222 | 0.86 | PNMT (0.58) | PNMTADRA2AADRA2BADRA2CDRD2 | |
| SCHEMBL329985 | 0.81 | ASIC3 (0.60) | PNMTADRA2AADRA2BADRA2CDRD2 | |
| SCHEMBL29657674 | 0.81 | ASIC3 (0.60) | PNMTADRA2AADRA2BADRA2CDRD2 | |
| Hydrochloric Acid SCHEMBL4514463 | 0.79 | ASIC3 (0.58) | PNMTADRA2AADRA2BADRA2CDRD2 | |
| Hydrochloric Acid SCHEMBL1948668 | 0.79 | ASIC3 (0.58) | PNMTADRA2AADRA2BADRA2CDRD2 | |
| SCHEMBL4718936 | 0.78 | PNMT (0.47) | PNMTADRA2AADRA2BADRA2CDRD2 | |
| 1,2,3,4-Tetrahydroisoquinoline SCHEMBL6451019 | 0.78 | PNMT (0.73) | PNMTADRA2AADRA2BADRA2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6608193-B2 | Forming an intermediate by reacting the support-bound amino-substituted-tetrahydroisoquinoline compound with a reagent; and cyclizatively cleaving support-bound amino-substituted-tetrahydroisoquinoline compound | THE PROCTER & GAMBLE COMPANY | 2003-08-19 | — | — | US | claimed |
| US-20020077480-A1 | Methods for synthesis of amino-tetrahydroisoquinoline ring compounds | PROCTER & GAMBLE COMPANY, THE | 2002-06-20 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020077480-A1 | Methods for synthesis of amino-tetrahydroisoquinoline ring compounds | ASNS, QPCT, DAO | PNMT 26/4885ADRA2A 3665/4885ADRA2B 3599/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.